Eli Lilly and Company
- Ticker
- LLY
- Exchange
- NYSE
- Country
- USA
Price History
Business
Company profile
AER Insights
Biotechnology & HealthcareJaypirca Moves Into First-Line CLL, Expanding Lilly’s Oncology Opportunity in a Crowded Market
FDA approval brings Lilly’s noncovalent BTK inhibitor into initial treatment for eligible patients with chronic lymphocytic leukemia. The commercial opportunity now extends earlier in the disease course, while competing targeted therapies, treatment duration and tolerability will determine how much of that opportunity becomes revenue.
Biotechnology & HealthcareFoghorn Lost Its Lilly Partnership, but the 40% Workforce Cut Changes the Valuation Math
Foghorn Therapeutics has discontinued FHD-909 and effectively ended a collaboration that brought in $380 million of upfront cash and equity from Lilly. The clinical failure removes its most advanced partnered asset, but a 40% workforce reduction extends cash runway into the second half of 2029 and leaves the company with $167.6 million of June cash and securities against a market value of roughly $200 million.
Financials
Fundamental data
Market information is supplied by TradingView and may be delayed or unavailable for certain exchanges or instruments. It does not constitute investment advice.
Alliance Equity Research Coverage
No current AER coverage
Related AER Insights are available above. This company does not currently have published AER company coverage.
Request Coverage